NCT06917001View on ClinicalTrials.gov

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Dengue Fever
Interventions
DRUG

Resomelagon

Resomelagon 100mg, orally, once daily.

DRUG

Placebo

Placebo

OTHER

Standard Treatment

Hydration and symptomatic therapy as indicated for Dengue fever.

Trial Locations (2)

15090000

Centro Integrado de Pesquisa, São José do Rio Preto

30750140

Clinical Research Unit, Belo Horizonte

All Listed Sponsors
collaborator

Instituto Nacional de Ciência e Tecnologia em Dengue (INCT em Dengue)

UNKNOWN

lead

Federal University of Minas Gerais

OTHER